Furthermore, there has been increased interest in combining BET and JAK inhibitor treatment for myeloproliferative neoplasms (MPN) as JAK/BET inhibition results in a marked reduction in serum inflammatory cytokines, reduced disease burden and reversed bone marrow fibrosis in vivo in mouse MPN models (48). This evidence concerns the gene DNER and myeloproliferative disorder.